Ecnoglutide Dosage Chart - Peptide Dosages

Ecnoglutide (10 mg) Dosage Protocol

A once-weekly, cAMP-biased GLP-1 receptor agonist (XW003) developed by Sciwind Biosciences. Approved by China’s NMPA in 2026 for type 2 diabetes and for chronic weight management — but not FDA-approved, and research-grade vials sold online are not the approved product.

A once-weekly GLP-1 receptor agonist engineered to be cAMP-biased: it strongly activates the cAMP pathway (EC50 about 0.018 nM) but minimally recruits beta-arrestin / receptor internalization (EC50 above 10 micromolar). An Ala8-to-Val change plus a C18 diacid fatty-acid chain binds albumin and gives a 124-138 hour half-life.

Once weekly subcutaneously, titrated. Type 2 diabetes trials used 0.6-1.2 mg/week; the phase 3 obesity trial used 1.2, 1.8 or 2.4 mg/week. A 10 mg vial in 2 mL bacteriostatic water is 5 mg/mL, so 1.2 mg = 0.24 mL (24 units) and 2.4 mg = 0.48 mL (48 units).

Approved by China NMPA in 2026 for type 2 diabetes and chronic weight management. In the phase 3 obesity trial (n=664) the 2.4 mg dose produced a placebo-adjusted weight reduction of about 13.3% at 40 weeks. Not FDA-approved; all pivotal trials were conducted in China.

Quickstart Highlights

Ecnoglutide (development code XW003), from Hangzhou Sciwind Biosciences, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist engineered to be “cAMP-biased” — in cell assays it potently triggers the receptor’s cAMP second-messenger pathway (EC₅₀ ≈ 0.018 nM) while barely driving receptor internalization (EC₅₀ > 10 µM), a deliberate signalling bias its developers argue simplifies manufacturing and may shape tolerability[1]. Structurally it is a GLP-1 analog carrying an Ala8→Val substitution plus a γGlu-2×AEEA-linked C18 diacid fatty-acid chain that binds albumin and stretches its half-life to roughly 124–138 hours — long enough for once-weekly subcutaneous dosing[1].

This page is an educational reference on how ecnoglutide has been dosed in its published clinical trials. It is not medical advice. Ecnoglutide was approved by China’s National Medical Products Administration (NMPA) in 2026 — first for type 2 diabetes, then for chronic weight management — and is being commercialised in China by Pfizer, but it is not approved by the FDA or any Western regulator, and a research-grade vial bought online is not the finished, quality-controlled product those approvals cover.

Mix & measure Ecnoglutide · 10 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Supplies Needed

Ecnoglutide is a subcutaneous injectable in research form, so the generic reconstitution kit below applies. The approved Chinese product ships in its own quality-controlled presentation; the workflow here is the standard one used across this site for research vials.

Protocol Overview

The practical picture is a single weekly subcutaneous injection of a small volume — between 12 and 48 units of a 5 mg/mL solution, depending on where in the titration a protocol sits. There is no daily schedule, no meal timing and no weight-based calculation; the dose is a fixed weekly milligram amount stepped up over the first weeks.

What separates ecnoglutide from the older weekly GLP-1 drugs on paper is its signalling bias and its manufacturing story, not a proven clinical edge. Its own phase 3 head-to-head against dulaglutide met non-inferiority and even reached statistical superiority at 1.2 mg, but the investigators themselves judged the difference not clinically relevant[4]. For anyone comparing it to semaglutide or tirzepatide, the honest answer is that no such head-to-head has been run.

Dosing Protocol

Reference volumes at the reconstitution used here (10 mg vial in 2 mL → 5 mg/mL). The dose column lists the actual weekly targets used in the published trials; a real protocol titrates up to one of them over several weeks. These reproduce studied doses and are not a recommendation to self-administer.

0.6 mg — diabetes starting/target[5]

0.12 mL

12 units

1.2 mg — diabetes target[4]

0.24 mL

24 units

1.8 mg — weight-management[3]

0.36 mL

36 units

2.4 mg — weight-management, highest studied[3]

0.48 mL

48 units

Why Ecnoglutide draws research interest

These are the directions researchers and the peptide community most often explore Ecnoglutide for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Approved in China, not the FDA

Ecnoglutide cleared China’s NMPA in 2026 — the world’s first cAMP-biased GLP-1 approved for weight management — and Pfizer is handling its Chinese launch. It has no FDA or EMA approval, and a grey-market research vial is not the manufactured product those approvals describe.

The “bias” is a hypothesis, not proven superiority

The cAMP-biased design is marketed as gentler and easier to make, but the head-to-head phase 3 against dulaglutide found its HbA1c edge “not clinically relevant,” and it has never been compared head-to-head with semaglutide or tirzepatide. The bias is a plausible mechanism, not a demonstrated advantage over other GLP-1 drugs.

Every pivotal number is from a Chinese population

The phase 2 and all three phase 3 trials enrolled Chinese adults. That is a strength for the approval it earned and a genuine caveat for anyone generalizing the weight-loss and glucose figures to other populations, where responses to GLP-1 agents can differ.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

2 mL bacteriostatic water per 10 mg vial → 5 mg/mL. At that concentration 1.2 mg = 24 units (0.24 mL) and 2.4 mg = 48 units (0.48 mL), both well within a 1 mL insulin syringe.

Published trials titrated to 0.6–1.2 mg/week for type 2 diabetes[5] and 1.2–2.4 mg/week for weight management[3], started low and stepped up to limit nausea.

Subcutaneous, once weekly, any day, with or without food, rotating sites. The long ~124–138 h half-life is what allows weekly dosing[1].

NMPA-approved in China (2026) for type 2 diabetes and weight management, backed by phase 3 trials[3][4][5]. Not FDA-approved. All pivotal data are in Chinese adults.

Dosing & Reconstitution Guide

Ecnoglutide is one of the few compounds on this site with public human dosing from completed phase 3 trials — but those doses come from a Chinese diabetes and obesity program, not an FDA label, and the research-grade vial you can buy is not the approved product[3][5]. Dosing is weight-independent, once weekly, and titrated upward to blunt gastrointestinal side effects, exactly as with other GLP-1 agonists.

Standard / Gradual Approach

In type 2 diabetes, the phase 3 monotherapy trial (EECOH-1) tested 0.6 mg and 1.2 mg once weekly[5], and the active-controlled trial (EECOH-2) compared those same two doses against dulaglutide 1.5 mg[4]. In weight management, the phase 3 SLIMMER trial used higher target doses of 1.2, 1.8 and 2.4 mg once weekly[3]. Across the program the pattern is consistent: start at a low weekly dose and escalate in steps every few weeks toward the target, because the dose-limiting effects are gastrointestinal (nausea, diarrhoea) rather than anything abrupt.

At a reconstitution of 10 mg in 2 mL (5 mg/mL), the whole published dose range fits comfortably in a single U-100 insulin syringe: 0.6 mg is 12 units, 1.2 mg is 24 units, 1.8 mg is 36 units and 2.4 mg is 48 units. Because the half-life is roughly 124–138 hours[1], a missed day matters little, but the once-weekly rhythm should be kept consistent so exposure stays even.

There is no established dose above 2.4 mg/week in the published trials, and pushing past the studied range trades the plateau of benefit for a steeper rise in nausea and vomiting. The meta-analysis of four randomized trials (1,643 participants) put the average glycaemic effect at an HbA1c reduction of 0.44 percentage points versus comparators and an average weight reduction of about 5.6 kg, with adverse events modestly more common than control but predominantly mild-to-moderate and gastrointestinal[6].

Reconstitution Steps

A research vial is lyophilized powder that must be reconstituted with bacteriostatic water. Using 2 mL for a 10 mg vial keeps the concentration at a clean 5 mg/mL, which makes the weekly dose arithmetic simple and keeps every dose inside a 1 mL syringe.

▪Sanitize: swab the vial stopper and the bacteriostatic-water stopper with fresh alcohol pads and let them air-dry.

▪Add 2 mL slowly: draw 2 mL of bacteriostatic water and let it run down the inside wall of the vial rather than jetting it onto the powder. This yields 5 mg/mL.

▪Dissolve gently: let it stand about 30 seconds, then swirl or roll the vial between your palms. Do not shake — shaking foams and can shear peptide in solution. Do not use it if the solution is cloudy or holds particles.

▪Refrigerate: store the reconstituted vial at 2–8 °C and use within the multi-week window bacteriostatic water supports; never freeze a reconstituted peptide.

Storage Instructions

Lyophilized vials are stable refrigerated and should be protected from light; follow the supplier’s handling guidance for the unreconstituted powder. Do not freeze a vial once it has been reconstituted.

After reconstitution with bacteriostatic water, store at 2–8 °C and use within the multi-week window the preservative supports. A research vial reconstituted this way is not the same preparation the approved product’s stability data describe, so err toward shorter storage and discard anything cloudy or discoloured.

Important Notes

The points below are the ones most often flattened when ecnoglutide is discussed as just another interchangeable weekly GLP-1 shot.

▪Approved in China, investigational everywhere else: the NMPA cleared ecnoglutide in 2026 for type 2 diabetes and, separately, for chronic weight management[3]. It carries no FDA or EMA approval. A research-grade vial is not the manufactured, quality-controlled product those Chinese approvals rest on — identity, fill and purity are unverified.

▪The weight-loss numbers are real, peer-reviewed, and from a 40-week Chinese trial: in SLIMMER (n=664, no diabetes), 40 weeks of once-weekly ecnoglutide produced least-squares mean weight changes of −9.1%, −10.9% and −13.2% at 1.2, 1.8 and 2.4 mg versus +0.1% on placebo, and 77–87% of participants lost at least 5% of body weight versus 16% on placebo[3]. Some promotional material quotes a higher “15%” figure; the peer-reviewed placebo-adjusted result at the top dose is about 13.3%.

▪Gastrointestinal effects are the dose-limiter, as with the whole class: treatment-emergent adverse events occurred in roughly 93% of ecnoglutide participants versus 84% on placebo in SLIMMER, most commonly mild-to-moderate nausea, diarrhoea and related GI symptoms; ten ecnoglutide participants discontinued for adverse events[3]. The class warnings that apply to other GLP-1 agonists (pancreatitis, gallbladder events, and the animal C-cell/thyroid signal) warrant the same caution here.

▪No head-to-head against semaglutide or tirzepatide: ecnoglutide has only been compared with dulaglutide[4] and with placebo. Any claim that it matches or beats the market-leading incretin drugs on weight or glucose is an extrapolation, not a trial result.

▪It appears not to disturb warfarin or metformin: a dedicated drug-interaction study found no clinically significant change in the exposure of metformin or either warfarin enantiomer, and warfarin’s INR was unaffected, so no dose adjustment of those two drugs was needed on co-administration[7]. That is reassuring but narrow — it speaks to two drugs, not to polypharmacy in general.

▪A research vial is not the approved injection: the Chinese product is a defined, quality-controlled formulation dispensed under prescription. A grey-market vial has none of that — no verified potency, no matched device, and no medical oversight of the titration, side effects or the class monitoring the label assumes.

How This Works

GLP-1 is an incretin hormone released by intestinal L-cells after eating; it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite through central pathways. Ecnoglutide is a synthetic GLP-1 analog built to survive in the body far longer than the native hormone and to hit the receptor in a particular way[1].

The distinctive part is the signalling bias. In receptor assays, ecnoglutide is an extremely potent activator of the cAMP pathway (EC₅₀ ≈ 0.018 nM) but a very weak driver of receptor internalization / β-arrestin recruitment (EC₅₀ > 10 µM)[1]. In principle, keeping the receptor on the cell surface rather than pulling it inside could sustain glucose-lowering signalling; in practice, whether this bias translates into a real clinical advantage over balanced agonists is not yet demonstrated in humans.

The long action comes from the fatty-acid chemistry: the C18 diacid chain, joined through a γGlu-2×AEEA linker, binds circulating albumin and slows clearance, giving a steady-state half-life of about 124–138 hours and supporting once-weekly injection[1]. In preclinical rodent models, ecnoglutide reduced blood glucose, boosted insulin and produced weight loss, which the phase 2 and phase 3 human trials then bore out as HbA1c reductions of roughly 2% and clinically meaningful weight loss[2][5].

Lifestyle Factors

Ecnoglutide, like every GLP-1 agonist, works best as an adjunct to diet and activity rather than a substitute for them. In the trials it was studied alongside lifestyle counselling; the appetite suppression it produces is the lever, but the durable outcome depends on the eating and movement patterns built around it[3].

Because the drug slows gastric emptying and blunts appetite, the practical daily reality is smaller portions and earlier fullness — which makes protein intake and hydration worth deliberate attention, since reduced overall intake can otherwise erode both. Rapid weight loss on any GLP-1 agent also raises the standing question of lean-mass preservation, for which resistance training and adequate protein are the established countermeasures. None of this is specific research on ecnoglutide; it is the generic, well-established context for the class.

Potential Benefits & Side Effects

Evidence tier: approved drug in China with positive phase 3 data — genuinely strong, and genuinely bounded to the populations studied. Everything below was measured in Chinese adults with type 2 diabetes or with obesity, and none of it has been tested head-to-head against the market-leading GLP-1 drugs.

Reported Effects

▪Weight loss — the headline phase 3 result: in SLIMMER (n=664, no diabetes), 40 weeks produced least-squares mean weight changes of −9.1%, −10.9% and −13.2% at 1.2, 1.8 and 2.4 mg versus +0.1% on placebo (all p<0.0001)[3].

▪Responders: 77%, 84% and 87% of participants at 1.2, 1.8 and 2.4 mg lost at least 5% of body weight, versus 16% on placebo[3].

▪Glucose control: in the phase 3 monotherapy diabetes trial, HbA1c fell by 1.96% (0.6 mg) and 2.43% (1.2 mg) versus 0.87% on placebo at 24 weeks[5]; the phase 2 trial had already shown reductions up to 2.39%[2].

▪Non-inferior to dulaglutide: against dulaglutide 1.5 mg over 52 weeks, both ecnoglutide doses were non-inferior on HbA1c and 1.2 mg was statistically superior — though the investigators called that difference not clinically relevant[4].

▪What is not established: any superiority over semaglutide or tirzepatide, any cardiovascular-outcome benefit, and any efficacy or safety data outside Chinese trial populations.

Common Side Effects

▪Gastrointestinal — the dominant signal: treatment-emergent adverse events reached about 93% on ecnoglutide versus 84% on placebo in SLIMMER, most commonly mild-to-moderate nausea, diarrhoea and related GI effects[3].

▪Discontinuations: ten ecnoglutide participants stopped treatment for adverse events across the 40-week obesity trial[3]; discontinuations for adverse events in the 52-week diabetes trial were 3–4% per group[4].

▪Class risks to respect: the GLP-1 class carries warnings for pancreatitis, gallbladder disease, and a rodent thyroid C-cell tumour signal; these are class considerations that apply here even where ecnoglutide’s own trials were not powered to resolve them.

▪Titration matters: nausea and vomiting rise if the dose is escalated too quickly — the studied schedules started low and stepped up specifically to keep GI effects tolerable.

▪Population caveat: the entire safety database is Chinese-trial data; tolerability in other populations, in pregnancy, or in combination with other weight or glucose drugs is not defined.

Injection Technique

Ecnoglutide is given by subcutaneous injection once weekly. The steps below are the generic subcutaneous workflow used across this site; they describe how the compound is handled, not a recommendation to self-treat with a non-FDA-approved drug.

Pre-Injection Preparation

▪Confirm the concentration: every volume here assumes 5 mg/mL — a 10 mg vial in 2 mL. A different diluent volume changes every unit figure.

▪Inspect: the reconstituted solution should be clear and particle-free; discard it if cloudy or discoloured.

▪Rotate the site: alternate among the abdomen (away from the navel) and the thighs to avoid repeated injection into one area.

Injection Procedure

▪Draw the weekly volume: the fixed milligram target for that week, converted at 5 mg/mL — for example 0.24 mL (24 units) for 1.2 mg.

▪Inject subcutaneously: pinch the skin, insert at the angle suited to the needle length, and deliver slowly into subcutaneous tissue — not intramuscular or intravenous.

▪Keep the weekly rhythm: the same day each week keeps exposure even; timing relative to meals does not matter for a weekly agent.

Post-Injection Care

▪Escalate slowly: if following the trial schedules, step the dose up only every few weeks — rushing the titration is what turns tolerable nausea into vomiting and dropout[3].

▪Watch for GI and class warning signs: persistent severe abdominal pain (a pancreatitis flag), gallbladder symptoms, or intractable vomiting warrant stopping and seeking medical care.

▪Store the vial properly between doses: refrigerate the reconstituted solution at 2–8 °C, never freeze it, and discard it if it turns cloudy.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for Ecnoglutide (10 mg Vial).

Why Prime Lab Peptides?

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.

▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.

▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.

▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.

▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

References

View Source ↗

Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.

There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.

On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.

Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.

Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.

No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

New protocols & dosing updates

Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.

Written by Dr. Aimen Arij, PharmD

Related Metabolic / GLP-1 protocols